Schedule 13G ownership disclosure

BIOXCEL THERAPEUTICS INC

Common Stock, par value $0.001 per share · CUSIP: 09075P204

Event date: 2025-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Integrated Core Strategies (US) LLC

    Shares: 1,833,717.00 · Class: 8.4%

  • Millennium Management LLC

    Shares: 1,835,192.00 · Class: 8.4%

  • Millennium Group Management LLC

    Shares: 1,835,192.00 · Class: 8.4%

  • Israel A. Englander

    Shares: 1,835,192.00 · Class: 8.4%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-26-012072
Form type
SCHEDULE 13G/A
Filer
BioXcel Therapeutics, Inc.
CIK
CIK 1720893
Filed
Feb 09, 2026
Reporting period
Dec 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub